New York TimesImportant note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu
DonateNow
Print this Article


Drug Trials Deepen Dilemma on Preventing H.I.V. Transmission in Breast-Feeding

The New York Times - July 29, 2008
Donald G. Mcneil Jr.


For a mother infected with the virus that causes AIDS, breast-feeding presents a life-and-death dilemma. Using formula protects her child from H.I.V. But mixed with dirty water, it increases the chances that the child will die of diarrhea or malnutrition. In poor countries, most mothers still breast-feed, because it is traditional, because formula is expensive - and because using formula announces to local busybodies that a mother is probably infected.

As a result, at least 150,000 babies are infected by their mothers each year through breast-feeding, experts estimate.

In trying to prevent that, AIDS researchers have stumbled into their own terrible dilemma. One dose of nevirapine, an inexpensive antiretroviral drug, can prevent mother-to-child transmission. But a single dose doesn't always work. And nevirapine can be dangerous; some infants develop liver failure, rashes or low white blood cell counts. Also, resistance to it develops quickly, meaning that a child who gets nevirapine and becomes infected anyway will be unable to take triple-therapy cocktails containing it or any related drug.

Last week, the journal The Lancet described trials in which 2,000 babies in Ethiopia, India and Uganda were given six weeks of nevirapine while breast-feeding. The trials, which found that six weeks was not clearly protective, only added to the controversy - a Lancet editorial called some results "head scratchers."

The principal authors suggested that infants might therefore need more nevirapine. But some of the Indian investigators dissented publicly, saying in a letter to The Lancet that the drug was too risky and that safer formula-feeding should be encouraged instead.


080729
NYT080723


Copyright © 2008 - The New York Times Company. All Rights Reserved. All New York Times articles contained on the AEGiS web site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of The New York Times Company. You may not alter or remove any trademark, copyright or other notice from copies of the content. However, you may download articles (one machine readable copy and one print copy per page) for your personal, noncommercial use only.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .